STEPHEN GEORGE DILLY - 28 Jan 2022 Form 4 Insider Report for Sierra Oncology, Inc.

Role: CEO and President, Director
Signature: /s/ Stephen George Dilly / By: Mary Christina Thomson, Attorney-In-Fact
Issuer symbol: N/A
Transactions as of: 28 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 28 Jan 2022, 17:32:31 UTC
Previous filing: 17 Jun 2021
Next filing: 14 Mar 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SRRA	Stock Option (Right to Buy)	Award	$0	+65,000		$0.000000	65,000	28 Jan 2022	Common Stock	65,000	$12.15	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 12, 2020, the Reporting Person was granted an option to purchase 260,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 65,000 shares.